Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 714
- Registration Number
- NCT05182840
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸PrimeCare Medical Group, Houston, Texas, United States
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
- Conditions
- Interventions
- First Posted Date
- 2021-12-30
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 26
- Registration Number
- NCT05174507
- Locations
- 🇨🇭
Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Basel, Switzerland
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Getz Pharma
- Target Recruit Count
- 156
- Registration Number
- NCT05164263
- Locations
- 🇱🇰
NHK, Kandy, Sri Lanka
🇵🇰Umar Diabetes Foundation, Islamabad, Pakistan
🇱🇰NHSL, Colombo, Sri Lanka
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 494679
- Registration Number
- NCT05162014
- Locations
- 🇩🇪
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT05140694
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
- Conditions
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05102071
- Locations
- 🇺🇸
Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States
A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT05083949
- Locations
- 🇧🇷
Instituto de Ciências Farmacêuticas de Estudos e Pesquisas - ICF, Goiânia, Brazil
Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
- Conditions
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 10
- Registration Number
- NCT05078879
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- EMS
- Target Recruit Count
- 480
- Registration Number
- NCT05028140
Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin
- Conditions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Hong Kong Children's Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT04986735
- Locations
- 🇭🇰
Hong Kong Children's Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.